Humacyte, Inc. (HUMA) Spending and interest coverage
- R&D / revenue · 12 months: Value 3276.00%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 504.90%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3276.00% | Research and development expense / revenue. Period ending 2026-06-30. $69.48M ÷ $2.12M × 100 ≈ 3276.00% |
| Stock-based compensation / revenue · 12 months | 504.90% | Share-based compensation / revenue. Period ending 2026-06-30. $10.71M ÷ $2.12M × 100 ≈ 504.90% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 69.48M USD | Research and Development Expense |
| Revenue | 2.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 10.71M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -111.16M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $69.48M | $2.12M | $10.71M | $-111.16M | (m) | 3276.00% | 504.90% | (m) | (m) |
| 2026-03-31 | $73.35M | $2.02M | $10.44M | $-113.89M | (m) | 3638.19% | 517.66% | (m) | (m) |
| 2025-12-31 | $69.30M | $2.04M | $9.75M | $-108.14M | (m) | 3400.49% | 478.56% | (m) | (m) |
| 2025-09-30 | $75.35M | (m) | $8.98M | $-105.39M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $81.01M | (m) | $8.07M | $-111.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $82.75M | (m) | $7.17M | $-111.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $88.60M | (m) | $6.14M | $-114.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $88.12M | (m) | $5.85M | $-112.49M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $83.75M | (m) | $6.07M | $-106.88M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $80.54M | (m) | $6.47M | $-104.11M | $6.72M | (m) | (m) | -15.50× | Reported |
| 2023-12-31 | $76.55M | (m) | $6.83M | $-100.05M | $6.60M | (m) | (m) | -15.16× | Reported |
| 2023-09-30 | $71.33M | (m) | $7.09M | $-94.66M | $6.51M | (m) | (m) | -14.54× | Reported |
| 2023-06-30 | $70.11M | (m) | $6.80M | $-93.53M | $6.69M | (m) | (m) | -13.98× | Reported |
| 2023-03-31 | $64.22M | (m) | $6.45M | $-85.33M | $6.47M | (m) | (m) | -13.19× | Reported |
| 2022-12-31 | $63.26M | (m) | $6.18M | $-84.58M | $6.20M | (m) | (m) | -13.64× | Reported |
| 2022-09-30 | $64.55M | (m) | $7.33M | $-85.42M | $5.96M | (m) | (m) | -14.34× | Reported |
| 2022-06-30 | $62.60M | (m) | $7.73M | $-82.46M | $5.52M | (m) | (m) | -14.94× | Reported |
| 2022-03-31 | $62.52M | (m) | $9.16M | $-83.20M | $5.25M | (m) | (m) | -15.86× | Reported |
| 2021-12-31 | $61.34M | (m) | $10.15M | $-81.21M | $4.35M | (m) | (m) | -18.68× | Reported |
| 2021-09-30 | (m) | (m) | (m) | $-4.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-987.01K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |